Fatal haemorrhage following liver biopsy in patients with HIV infection

Duncan R Churchill, Darren Mann, Richard J Coker, Robert F Miller, Geoffrey Glazer, Robert D Goldin, Sebastian B Lucas, Jonathan N Weber, Kevin M De Cock

A retrospective review of all 248 liver biopsies performed in patients with HIV infection at two referral centres in London over a 12 year period revealed five cases of major bleeding following biopsy, with four deaths. The risk of major bleeding was 2.0%, and mortality was 1.6% following liver biopsy. The risk of bleeding was much higher than in published series of biopsies done in patients without HIV infection, owing in part to the high prevalence of thrombocytopaenia and clotting abnormalities in patients with HIV infection. HIV infection per se may also increase the risk of bleeding following liver biopsy.

(*Genitourin Med* 1996;72:62-64)

Keywords: HIV; liver biopsy; haemorrhage

Introduction

Percutaneous biopsy of the liver is a well-established technique, complicated by significant bleeding in one in every 200-300 patients.^{1,2} Recently, several case reports have suggested that patients who are HIV-infected may be more likely to bleed following liver biopsy.^{3,4} A retrospective review at two HIV units in London revealed five cases of major bleeding, of which four were fatal, following liver biopsy in 248 patients with HIV infection.

Case report

A 41 year old homosexual man (Patient 1; table 1) was admitted to hospital for investigation of an unexplained fever and sweats which had persisted for 3 months. He had been found to be HIV-1 antibody positive 2 years previously, and subsequently had had oral candidiasis, recurrent genital herpes simplex infection, and anogenital warts. He gave a history of fully-treated syphilis and asymptomatic hepatitis B infection (with persistently negative tests for both surface antigen and e antigen). Four years before admission, he had received a standard six month course of triple therapy for a clinical diagnosis of pleural/pulmonary tuberculosis. He was taking co-trimoxazole 960 mg daily as primary prophylaxis against *Pneumocystis carinii* pneumonia, and isoniazid 300 mg daily as secondary prophylaxis against tuberculosis. His CD4 lymphocyte count was $120 \times 10^9/l$ (12%; normal range $350-2200 \times 10^9/l$). Clinical examination revealed hepatosplenomegaly, and a fever of up to $40^\circ C$. Investigations including culture of urine, stool, bone marrow aspirate and multiple peripheral blood samples; serology for *Brucella*, *Coxiella*, *Histoplasma capsulatum*, *Cryptococcus neoformans* and *Entamoeba histolytica*; blood films for malaria; an autoantibody profile; a chest radiograph, intravenous pyelogram, abdominal ultrasound scan and abdominal computed tomography (CT) scan all failed to identify the cause of fever. During

the course of his investigation progressive abnormalities of liver function tests were noted, with an alkaline phosphatase enzyme level rising to over 5 times the upper limit of normal; bilirubin and transaminase enzymes remained normal. Thrombocytopaenia also developed, with the platelet count falling to $32 \times 10^9/l$, before spontaneously rising over ten days to $64 \times 10^9/l$. In view of the abnormal liver function tests and history of tuberculosis, a granulomatous hepatitis was suspected, and a liver biopsy was planned. Because of thrombocytopaenia and a mildly prolonged prothrombin time (15 seconds; control 12 seconds), and after review by a consultant haematologist, he was given 10 mg of intravenous vitamin K on three successive days. Transfusions of fresh frozen plasma (4 units) and platelet concentrate (4 units) were given immediately before the biopsy; this increased the platelet count to $104 \times 10^9/l$. The procedure was done under ultrasound guidance, by an experienced operator, using a Biopty gun (18G needle). Two passes were performed, and liver tissue was obtained on both occasions. There were no immediate complications. Four hours after the procedure the patient showed signs of intraperitoneal haemorrhage. Ultrasound of the abdomen showed a large subcapsular haematoma with a small amount of free abdominal fluid. Despite aggressive management with transfusion of blood, platelets and clotting factors, there were persisting signs of haemorrhage, and a laparotomy was performed. This revealed two small puncture wounds in the liver capsule with continued oozing, and five litres of blood in the peritoneal cavity. Despite packing of the wound and continued transfusion, the patient died 20 hours after the liver biopsy. Histology of the biopsy specimen showed a non-specific hepatitis of unknown aetiology. Post-mortem examination confirmed that bleeding from the liver biopsy was the cause of death and failed to reveal the cause of the patient's fever.

Over 12 years, our two HIV units have performed 248 liver biopsies. During this period

Department of
Genitourinary
Medicine/
Communicable
Diseases
D R Churchill
R J Coker
J N Weber

Department of
Surgery
D Mann
G Glazer

Department of
Histopathology, St
Mary's Hospital and
Medical School, Praed
St, London W2 1NY
R D Goldin

Inpatient Unit for
HIV/AIDS, Camden
and Islington
Community Health
Services Trust,
Middlesex Hospital
Site, Mortimer St,
London W1N 8AA
R F Miller
K M De Cock

Department of
Histopathology,
University College
London Medical
School, London
WC1E 6JJ
S B Lucas

Correspondence to:
Dr Kevin M De Cock,
Department of Clinical
Sciences, London School of
Hygiene and Tropical
Medicine, Keppel St,
London WC1E 7HT, UK.

Accepted for publication
27 November 1995

Table 1 Details of patients with bleeding following liver biopsy (FFP = Fresh frozen plasma).

Patient No	Age (years)	Sex	Prior AIDS	CD4+ count ($\times 10^6/l$)	PT (s)	Hb (g/l)	Platelets ($\times 10^9/l$)	Needle type	Histology	Surgery	Outcome	Notes
1	41	M	No	120	15	94	64 (increased to 104 after transfusion)	Biopsy gun Ultrasound guidance	Non-specific hepatitis	Laparotomy 16 hours	Died 20 hours	Vitamin K; 4 units platelets, 4 units FFP before biopsy
2	36	M	No	420	19	83	80	Menghini	Non-specific hepatitis	Failed embolisation; laparotomy	Died 24 hours	Vitamin K; 6 units platelets pre biopsy
3	46	M	Yes	N/A	14.4	111	26	Temno; Ultrasound guidance	Drug-related hepatitis	Laparotomy 24 hours	Survived	6 units platelets pre biopsy
4	30	M	Yes	N/A	16.7	103	154	Tru-cut	Non-specific hepatitis	Laparotomy 36 hours	Died 48 hours	
5	40	F	Yes	16	13	81	184	Tru-cut	Histoplasmosis	None	Died 5 hours	

Table 2 Final histological diagnoses following liver biopsy in 248 patients (NB fifteen patients had two diagnoses)

Viral infection	
Chronic Hepatitis B	86
Chronic Hepatitis C	37
Cytomegalovirus	5
Bacterial infection	
Mycobacterium avium-intracellulare	30
Mycobacterium tuberculosis	8
Protozoal infection	
Leishmania sp	5
Pneumocystis carinii	3
Microsporidium sp	1
Fungal infection	
Histoplasma capsulatum	4
Cryptococcus neoformans	3
Penicillium marneffei	1
Unidentified fungus	1
Malignancy	
Non-Hodgkin's lymphoma	8
Hepatocellular carcinoma	1
Drug reaction/Non-specific hepatitis	27
Miscellaneous	
Biliary obstruction	9
Peliosis hepatis	2
Alcoholic hepatitis	1
Fatty liver	1
No diagnosis/normal	30
Total	263

we have encountered four other cases of major bleeding (defined as bleeding requiring blood transfusion plus surgery/embolisation if clinically appropriate) following liver biopsy (table 1).

Discussion

Percutaneous biopsy of the liver in carefully selected patients results in serious haemorrhage in one patient in every 200–300 procedures. Liver biopsy was associated with mortality of between 0.01% and 0.11% in several large series.¹ In contrast to these figures, we encountered a rate of major haemorrhage of 2.0% and a mortality of 1.6% from liver biopsies in patients with HIV infection. Formal statistical comparison of complications between such heterogeneous groups is impossible, but the possibility is raised of an increased risk of complications of liver biopsy in patients with HIV infection.

Indications for liver biopsy in patients with HIV infection are numerous, and include the

investigation of fever, hepatomegaly, abnormal liver function tests or of focal lesions demonstrated on imaging studies. The majority of biopsies performed for these indications show abnormalities.⁵ Of the 248 biopsies performed for a variety of indications at our units (table 2), 70/222 (31.5%) revealed major opportunistic infections or tumours, whilst only 30 (13.5%) were normal. A number of criteria have been suggested for selection of patients for liver biopsy. The prothrombin time should be no more than 3 seconds prolonged,¹ or less than 16.7 seconds (control 10.2–12.3);² the platelet count at least $56 \times 10^9/l^2$ or $80 \times 10^9/l$;¹ and the haemoglobin concentration at least 89 g/l.² Imaging with ultrasound or CT before the procedure is recommended,¹ so that the best and safest area for biopsy can be selected. However, ultrasound or CT-guidance of biopsies probably need only be routine in patients with focal lesions.⁶

McGill *et al*² reported that the presence of malignancy, advanced age, female sex, and the number of passes with the biopsy needle were the only factors which predicted bleeding. Recently, however, major haemorrhage and death following liver biopsy have been recorded in five patients with AIDS.^{3,4} Four of these patients had no obvious risk factor for bleeding, whilst the fifth bled from previously unrecognised hepatic Kaposi's sarcoma. The high incidence of major bleeding we observed following liver biopsy may simply reflect the fact that three of our patients had clotting abnormalities and were thus at high risk of bleeding. Anaemia may also have contributed to the high mortality following haemorrhage from the biopsy site. However, it is also possible that HIV infection *per se* is associated with increased risk of bleeding following biopsy, perhaps due to unrecognised impairment of platelet function, undetected abnormalities of clotting, or ultrastructural abnormalities in the liver³ which might impair mechanical compression of the needle tract, as even in the face of entirely normal platelet levels and clotting tests, fatal haemorrhage may still occur.³

Although liver biopsy may be very useful in the management of patients with HIV infection,⁷ most of the infections and tumours which may affect the liver are disseminated,

and are present in other organs. Prego *et al*⁸ found that liver biopsy had a higher sensitivity and gave a more rapid result than blood culture or bone marrow biopsy in febrile HIV-infected patients with mycobacterial disease. Recently, however, Miralles *et al*⁹ reported that aspiration and biopsy of lymph nodes or bone marrow gave a higher diagnostic yield in HIV-infected patients with fever of unknown origin. The relative clinical utility of different investigations probably depends on the prevalence of different opportunistic infections such as tuberculosis and leishmaniasis in the community, and even if less invasive tests are performed initially, there will remain a group in whom liver biopsy is clearly indicated.⁷ Thrombocytopaenia, anaemia, and abnormalities of clotting tests are all common in patients with symptomatic HIV disease, both due to HIV infection itself and as a result of drug therapy.¹⁰ Nevertheless, it is essential that full correction of abnormalities is carried out before liver biopsy in patients with HIV infection, and if clotting abnormalities cannot be corrected, and it is deemed essential to perform a liver biopsy, transjugular or plugged percutaneous techniques should be used, depending on local expertise. With hindsight, these techniques would have been more appropriate than percutaneous needle biopsy

in cases 1–3. In the light of our experience, early intervention with surgery or hepatic artery embolisation should be considered in patients with HIV infection who have significant bleeding after liver biopsy.

- 1 Sherlock S, Dooley J. *Diseases of the Liver and Biliary System*. 9th ed. Oxford: Blackwell Scientific Publications 1993.
- 2 McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major haemorrhage after percutaneous liver biopsy. *Gastroenterology* 1990;**99**:1396–1400.
- 3 Gordon SC, Veneri RJ, McFadden RF, Reddy KR, Schiff ER. Major haemorrhage after percutaneous liver biopsy in patients with AIDS. *Gastroenterology* 1991;**100**:1787.
- 4 Gottesman D, Dyrszka H, Albarran J, Hilfer J. AIDS-related hepatic Kaposi's sarcoma: massive bleeding following liver biopsy. *Am J Gastroenterol* 1993;**88**:762–4.
- 5 Wilkins MJ, Lindley R, Dourakis SP, Goldin RD. Surgical pathology of the liver in HIV infection. *Histopathology* 1991;**18**:459–64.
- 6 Vautier G, Scott B, Jenkins D. Liver biopsy: guided or not? *BMJ* 1994;**309**:1455–6.
- 7 Cavicchi M, Pialoux G, Carnot F *et al*. Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated levels of alkaline phosphatase or γ -glutamyl transferase. *Clin Inf Dis* 1995;**20**:606–10.
- 8 Prego V, Glatt AE, Roy V, Thelmo W, Dinscoy H, Raufman JP. Comparative yield of blood culture for fungi and mycobacteria, liver biopsy and bone marrow biopsy in the diagnosis of fever of undetermined origin in human immunodeficiency virus-infected patients. *Arch Intern Med* 1990;**150**:333–6.
- 9 Miralles P, Moreno S, Perez-Tascon M, Cosin J, Diaz MD, Bouza E. Fever of uncertain origin in patients infected with the human immunodeficiency virus. *Clin Infect Dis* 1995;**20**:872–5.
- 10 Doweiko JP. Management of the haematologic manifestations of HIV disease. *Blood Reviews* 1993;**7**:121–6.